| __timestamp | BioCryst Pharmaceuticals, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 9136000 |
| Thursday, January 1, 2015 | 1896000 | 5807000 |
| Friday, January 1, 2016 | 2699000 | 5571000 |
| Sunday, January 1, 2017 | 1702000 | 5366000 |
| Monday, January 1, 2018 | 471000 | 6337000 |
| Tuesday, January 1, 2019 | 4101000 | 11347000 |
| Wednesday, January 1, 2020 | 1676000 | 30419000 |
| Friday, January 1, 2021 | 7264000 | 62176000 |
| Saturday, January 1, 2022 | 6594000 | 52827000 |
| Sunday, January 1, 2023 | 4661000 | 35049000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding the cost of revenue is crucial for evaluating a company's financial health. This analysis focuses on Ligand Pharmaceuticals Incorporated and BioCryst Pharmaceuticals, Inc., two prominent players in the industry. Over the past decade, Ligand Pharmaceuticals has consistently outpaced BioCryst in terms of cost of revenue, with figures peaking at approximately $62 million in 2021, a staggering 750% increase from 2014. In contrast, BioCryst's cost of revenue saw a more modest rise, reaching around $7.3 million in 2021, up from $122,000 in 2014. This disparity highlights Ligand's expansive growth strategy, while BioCryst maintains a more conservative approach. The data from 2014 to 2023 reveals significant fluctuations, reflecting the volatile nature of the biotech sector. Investors and analysts should consider these trends when assessing the financial strategies of these companies.
Eli Lilly and Company vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Johnson & Johnson vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Novartis AG vs Ligand Pharmaceuticals Incorporated
Walgreens Boots Alliance, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: ADMA Biologics, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Ligand Pharmaceuticals Incorporated and Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Iovance Biotherapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for BioCryst Pharmaceuticals, Inc. and Xencor, Inc.